




## Human IgG<sub>1</sub>κ Isotype Control

Cat. No.	Format	Size
0151K-01	Purified (UNLB)	0.5 mg
0151K-04	Alkaline Phosphatase (AP)	1.0 mL
0151K-05	Horseradish Peroxidase (HRP)	1.0 mL
0151K-09	R-phycoerythrin (PE)	0.1 mg
0151K-14	Low Endotoxin, Azide-Free (LE/AF)	0.5 mg
0151K-28	Biotin-maleimide (BIMA)	0.5 mg



ELISA plate was coated with serially diluted Human IgG1 Kappa-UNLB (SB Cat. No. 0151K-01). Immunoglobulin was detected with Mouse Anti-Human IgG1 Hinge-BIOT (SB Cat. No. 9052-08), Mouse Anti-Human IgG2 Fc-BIOT (SB Cat. No. 9060-08), Mouse Anti-Human IgG3 Hinge-BIOT (SB Cat. No. 9210-08), Mouse Anti-Human IgG4 pFc'-BIOT (SB Cat. No. 9190-08), Mouse Anti-Human IgA1-BIOT (SB Cat. No. 9130-08), Mouse Anti-Human IgA2-BIOT (SB Cat. No. 9140-08), Mouse Anti-Human IgD-BIOT (SB Cat. No. 9030-08), Mouse Anti-Human IgE Fc-BIOT (SB Cat. No. 9160-08), Mouse Anti-Human IgM-BIOT (SB Cat. No. 9020-08), Mouse Anti-Human Kappa-BIOT (SB Cat. No. 9230-08), and Mouse Anti-Human Lambda-BIOT (SB Cat. No. 9180-08) followed by Streptavidin-HRP (SB Cat. No. 7100-05) and quantified.

## Description

<b>Isotype</b>	Human IgG <sub>1</sub> κ
<b>Source</b>	Human myeloma serum

## Applications

Quality tested applications include –

ELISA <sup>1,2</sup>  
FLISA

Other referenced applications include –

FC <sup>8,9</sup>  
IP <sup>3</sup>  
*In vitro* control <sup>4-6</sup>  
*In vivo* control <sup>1,7</sup>  
Stim (Fc mediated) <sup>10</sup>  
Block <sup>6</sup>  
SPR <sup>1</sup>

## Working Dilutions

<b>ELISA</b>	Purified (UNLB) antibody	≤ 2 µg/mL
	BIMA conjugate	1:5,000 – 1:20,000
	AP and HRP conjugates	1:500 – 1:2,000

<b>FLISA</b>	PE conjugate	≤ 1 µg/mL
--------------	--------------	-----------

**Other Applications** Since applications vary, you should determine the optimum working dilution for the product that is appropriate for your specific need.

**For Research Use Only. Not for Diagnostic or Therapeutic Use.**

## Handling and Storage

---

- The purified (UNLB) IgG is supplied as 0.5 mg of purified immunoglobulin in 1.0 mL of borate buffered saline, pH 8.2. *No preservatives or amine-containing buffer salts added.* Store at 2-8°C.
- The alkaline phosphatase (AP) conjugate is supplied as 1.0 mL in a stock solution of 50 mM Tris/1 mM MgCl<sub>2</sub>/50% glycerol, pH 8.0, containing NaN<sub>3</sub> as preservative. Store at 2-8°C or long-term at -20°C.
- The horseradish peroxidase (HRP) conjugate is supplied as 1.0 mL in a stock solution of 50% glycerol/50% PBS, pH 7.4. No preservative added. Store at 2-8°C or long-term at -20°C.
- The biotin (BIMA) conjugate is supplied as 0.5 mg in 1.0 mL of PBS/NaN<sub>3</sub>. Store at 2-8°C.
- The R-phycoerythrin (PE) conjugate is supplied as 0.1 mg in 1.0 mL of PBS/NaN<sub>3</sub> and a stabilizing agent. Store at 2-8°C. **Do not freeze!**
- The low endotoxin, azide-free (LE/AF) antibody is supplied as 0.5 mg purified immunoglobulin in 1.0 mL of PBS. **Aliquot and store at or below -20°C.**
- Protect fluorochrome-conjugated forms from light. Reagents are stable for the period shown on the label if stored as directed.
- If turbidity occurs, clarify the solution by centrifugation prior to use.

## Warning

---

Some reagents contain sodium azide. Please refer to product specific SDS.

## References

---

1. Bock F, Onderka J, Dietrich T, Bachmann B, Kruse FE, Paschke M, et al. Bevacizumab as a potent inhibitor of inflammatory corneal angiogenesis and lymphangiogenesis. *Invest Ophthalmol Vis Sci.* 2007;48:2545-52. (ELISA, *in vivo* control, Surface plasmon resonance)
2. Zhang J, Jacobi AM, Wang T, Berlin R, Volpe BT, Diamond B. Polyreactive autoantibodies in systemic lupus erythematosus have pathogenic potential. *J Autoimmun.* 2009;33:270-4. (ELISA)
3. Yang G, Holl TM, Liu Y, Li Y, Lu X, Nicely NI, et al. Identification of autoantigens recognized by the 2F5 and 4E10 broadly neutralizing HIV-1 antibodies. *J Exp Med.* 2013;210:241-56. (IP)
4. Ackler S, Mitten MJ, Foster K, Oleksijew A, Refici M, Tahir SK, et al. The Bcl-2 inhibitor ABT-263 enhances the response of multiple chemotherapeutic regimens in hematologic tumors *in vivo*. *Cancer Chemother Pharmacol.* 2010;66:869-80. (*In vitro* control)
5. Li J, Jie H, Lei Y, Gildener-Leapman N, Trivedi S, Green T, et al. PD-1/SHP-2 inhibits Tc1/Th1 phenotypic responses and the activation of T cells in the tumor microenvironment. *Cancer Res.* 2015;75:508-18. (*In vitro* control)
6. Li J, Srivastava RM, ETTYREDDY A, Ferris RL. Cetuximab ameliorates suppressive phenotypes of myeloid antigen presenting cells in head and neck cancer patients. *J Immunother Cancer.* 2015;3:54. (*In vitro* control, Block)
7. Woess C, Tuzlak S, Labi V, Drach M, Bertele D, Schneider P, et al. Combined loss of the BH3-only proteins Bim and Bmf restores B-cell development and function in TACI-Ig transgenic mice. *Cell Death Differ.* 2015;22:1477-88. (*In vivo* control)
8. Hotard AL, Lee S, Currier MG, Crowe JE Jr, Sakamoto K, Newcomb DC, et al. Identification of residues in the human respiratory syncytial virus fusion protein that modulate fusion activity and pathogenesis. *J Virol.* 2015;89:512-22. (FC)
9. Chapuy CI, Nicholson RT, Aguad MD, Chapuy B, Laubach JP, Richardson PG, et al. Resolving the daratumumab interference with blood compatibility testing. *Transfusion.* 2015;55:1545-54. (FC)
10. Ortiz DF, Lansing JC, Rutitzky L, Kurtagic E, Prod'homme T, Choudhury A, et al. Elucidating the interplay between IgG-Fc valency and FcγR activation for the design of immune complex inhibitors. *Sci Transl Med.* 2016;8:365ra158. (Stim)
11. Liu H, Chumsae C, Gaza-Bulseco G, Hurkmans K, Radziejewski CH. Ranking the susceptibility of disulfide bonds in human IgG1 antibodies by reduction, differential alkylation, and LC-MS analysis. *Anal Chem.* 2010;82:5219-26. (Mass spectrometry)

In accordance with current Good Manufacturing and Good Laboratory Practices (cGMP/cGLP), any protein of human blood origin should be handled pursuant to your organization's documented safety procedures and as if it is capable of transmitting infection. This product has **NOT** been tested for viral, bacterial, or other infectious agents such as, but not limited to, HIV, HbsAg, and HCV.

TB0151K  
16-Feb-18

**Corporate Offices:** 160 Oxmoor Blvd • Birmingham, AL 35209 • USA **Mailing Address:** P.O. Box 26221 • Birmingham, AL 35260 • USA

**Tel:** 205.945.1774 • U.S. and Canada: 800.722.2255 • **Fax:** 205.945.8768

**Email:** [info@southernbiotech.com](mailto:info@southernbiotech.com) • **Website:** [www.southernbiotech.com](http://www.southernbiotech.com)